Elevated serum levels of a proliferation-inducing ligand in patients with systemic sclerosis: Possible association with myositis?

Joint Bone Spine

Volumn 78, Issue 1, 2011, Pages 56-61

  Bassyouni, Iman H ^a   Azab, Noha A ^a   El Dakrony, El Hussein M ^a   Fawzi, Marwa M T ^a   Ghanoum, Randa ^b   Bassyouni, Rasha H ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL HEART INSTITUTE   (Egypt)

^c FAYOUM UNIVERSITY   (Egypt)

Author keywords

A proliferation inducing ligand (APRIL); Myositis; Systemic sclerosis

Indexed keywords

APRIL PROTEIN; AUTOANTIBODY; C REACTIVE PROTEIN; CREATINE KINASE; IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EGYPT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG FIBROSIS; LUNG FUNCTION; MALE; MYOSITIS; PREVALENCE; SCORING SYSTEM; SYSTEMIC SCLEROSIS;

ADULT; AGED; C-REACTIVE PROTEIN; GAMMA-GLOBULINS; HUMANS; HYPERGAMMAGLOBULINEMIA; INCIDENCE; LUNG DISEASES; MIDDLE AGED; MYOSITIS; PREVALENCE; PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; YOUNG ADULT;

EID: 78651110762     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.05.004     Document Type: Article

References (40)

1. White B. Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 1996, 22:695-708.
2. Yazawa N., Fujimoto M., Tamaki K. Recent advances on pathogenesis and therapies in systemic sclerosis. Clin Rev Allergy Immunol 2007, 33:107-112.
3. Sato S., Fujimoto M., Hasegawa M., et al. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004, 50:1918-1927.
4. Saito E., Fujimoto M., Hasegawa M., et al. CD-19-dependant B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002, 109:1453-1462.
5. Hasegawa M., Hamaguchi Y., Yanaba K., et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006, 169:954-966.
6. Smith V.P., Van Praet J.T., Vandooren B.R., et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2008, doi: 0ard.2008.095463v1.
7. Lafyatis R., Kissin E., York M., et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009, 60:578-583.
8. Daoussis D., Liossis S.N., Tsamandas A.C., et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 2010, 49(2):271-280.
9. McGonagle D., Tan A.L., Madden J., et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology 2008, 47:552-553.
10. Okamoto M., Okano A., Akamatsu S., et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006, 20:172-173.
11. Mackay F., Schneider P., Rennert P., et al. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003, 21:231-264.
12. Kelly K., Manos E., Jensen G., et al. APRIL/TRDL-1, a tumor necrosis factor-like ligand, simulates cell death. Cancer Res 2000, 60:1021-1027.
13. Mackay F., Schneider P. T.A.C.I. an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev 2008, 19:263-276.
14. Wang H., Marsters S.A., Baker T., et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2001, 2:632-637.
15. Groom J., Kalled S.L., Cutler A.H., et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002, 109:59-68.
16. Mariette X., Roux S., Zhang J., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003, 62:168-171.
17. Stohl W., Metyas S., Tan S.M., et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003, 48:3475-3486.
18. Cheema G.S., Roschke V., Hilbert D.M., et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001, 44:1313-1319.
19. Krytufkova O., Vallerskog T., Barbasso Helmers S., et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic myopathies. Ann Rheum Dis 2009, 68(6):836-843.
20. Matsushita T., Hasegawa M., Yanaba K., et al. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006, 54(1):1-9.
21. Hegazy M., Darwish H., Darweesh H., et al. Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices. Clin Immunol 2010, 135:118-124.
22. Koyama T., Tsukamoto H., Miyagi Y., et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005, 64:1065-1067.
23. Jonsson Mv, Szodoray P., Jellestad S., et al. Association between the circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J Clin Immunol 2005, 25:189-201.
24. Matsushita T., Fujimoto M., Hasegawa M., et al. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 2007, 34:2056-2062.
25. Preliminary criteria for the classification of systemic sclerosis (scleroderma): Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
26. Le Roy E.C., Black C., Fleischmajer R., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
27. Clements P., Lachenbruch P., Seibold J., et al. Inter- and intraobserver variability of total skin thickness score (modified Rodan TSS) in systemic sclerosis. J Rheumatol 1995, 22:1281-1285.
28. Daniels L., Worthongham C. Muscle testing: techniques of manual examination. 1972, WB Saunders, Philadelphia, p. 2-3. 3rd edn.
29. Scala E., Pallotta S., Frezzolini A., et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004, 138(3):540-546.
30. Watanabe R., Fujimoto M., Yazawa N., et al. Increases serum levels of a proliferation-inducing ligand in patients with bullous pemphigoid. J Dermatol Sci 2007, 46(1):53-60.
31. Thangarajh M., Masterman T., Rot U., et al. Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis. J Neuroimmunol 2005, 167(1-2):210-214.
32. Ramanujam M., Wang X., Huang W., et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006, 16(3):724-734.
33. Kato A., Truong-Tran A.Q., Scott A.L., et al. Airway epithelial cells produce B cell-activating factor of TNF family by an IFN-beta-dependent mechanism. J Immunol 2006, 177:7164-7172.
34. Christopher-Stinea L., Plotz P. Myositis: an update on pathogenesis. Curr Opin Rheumatol 2004, 16:700-706.
35. Grundtman C., Malmström V., Lundberg I.E. Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis Res Ther 2007, 9(2):208.
36. Dalakas M.C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004, 291(19):2367-2375.
37. Le Pottier L., Bendaoud B., Dueymes M., et al. BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J Clin Immunol 2007, 27(3):257-265.
38. Noss E.H., Hausner-Sypek D.L., Weinblatt M.E. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006, 33:1021-1026.
39. Fabri M., Hunzelmann N., Krieg T., et al. Discordant response to rituximab in a systemic sclerosis patient with associated myositis. J Am Acad Dermatol 2008, 58(5 Suppl. 1):S127-S128.
40. Pope J. Musculoskeletal involvement in scleroderma. Rheum Dis Clin North Am 2003, 29:391-408.